托珠单抗治疗危重症 COVID-19 患者 1 例报告。
Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
机构信息
Department of Neurology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
出版信息
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5783-5787. doi: 10.26355/eurrev_202005_21372.
In December 2019, Coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread throughout China and the rest of the world. COVID-19 is currently a global pandemic. There are cytokine storms in severe COVID-19 patients. Interleukin-6 plays an important role in cytokine storm. Tocilizumab is a blocker of interleukin-6 receptor, which is likely to become an effective drug for patients with severe COVID-19. Here, we reported a case in which tocilizumab was effective for a critical COVID-19 patient.
2019 年 12 月，新型冠状病毒疾病 2019（COVID-19）在武汉出现，并迅速在中国和世界其他地区蔓延。COVID-19 目前是一种全球大流行疾病。在重症 COVID-19 患者中存在细胞因子风暴。白细胞介素-6 在细胞因子风暴中发挥重要作用。托珠单抗是白细胞介素-6 受体的阻滞剂，很可能成为重症 COVID-19 患者的有效药物。在这里，我们报告了一例托珠单抗对重症 COVID-19 患者有效的病例。
Zotero 插件